Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Endosc Int Open ; 9(10): E1572-E1578, 2021 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-34540553

RESUMO

Background and study aims The COVID-19 pandemic has had a profound impact on gastroenterology training programs. We aimed to objectively evaluate procedural training volume and impact of COVID-19 on gastroenterology fellowship programs in the United States. Methods This was a retrospective, multicenter study. Procedure volume data on upper and lower endoscopies performed by gastroenterology fellows was abstracted directly from the electronic medical record. The study period was stratified into 2 time periods: Study Period 1, SP1 (03/15/2020 to 06/30/2020) and Study Period 2, SP2 (07/01/2020 to 12/15/2020). Procedure volumes during SP1 and SP2 were compared to Historic Period 1 (HP1) (03/15/2019 to 06/30/2019) and Historic Period 2 (HP2) (07/01/2019 to 12/15/2019) as historical reference. Results Data from 23 gastroenterology fellowship programs (total procedures = 127,958) with a median of 284 fellows (range 273-289; representing 17.8 % of all trainees in the United States) were collected. Compared to HP1, fellows performed 53.6 % less procedures in SP1 (total volume: 28,808 vs 13,378; mean 105.52 ±â€Š71.94 vs 47.61 ±â€Š41.43 per fellow; P  < 0.0001). This reduction was significant across all three training years and for both lower and upper endoscopies ( P  < 0.0001). However, the reduction in volume was more pronounced for lower endoscopy compared to upper endoscopy [59.03 % (95 % CI: 58.2-59.86) vs 48.75 % (95 % CI: 47.96-49.54); P  < 0.0001]. The procedure volume in SP2 returned to near baseline of HP2 (total volume: 42,497 vs 43,275; mean 147.05 ±â€Š96.36 vs 150.78 ±â€Š99.67; P  = 0.65). Conclusions Although there was a significant reduction in fellows' endoscopy volume in the initial stages of the pandemic, adaptive mechanisms have resulted in a return of procedure volume to near baseline without ongoing impact on endoscopy training.

2.
Clin J Gastroenterol ; 13(2): 170-172, 2020 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-31541412

RESUMO

Esophageal pseudodiverticulosis is a rare endoscopic finding in eosinophilic esophagitis. We report a case of a 32-year-old male who presented with dysphagia and gastroesophageal reflux disease and was found to have esophageal pseudodiveritcula along with esophageal rings. The patient was subsequently treated with endoscopic balloon dilation and a diagnosis of eosinophilic esophagitis (EoE) with pseudodiverticulosis was made based upon the endoscopic and biopsy findings. This case provides evidence of the unusual finding of pseudodiverticulosis associated with EoE and further understanding of its pathogenesis is required.


Assuntos
Diverticulose Esofágica/etiologia , Esofagite Eosinofílica/complicações , Adulto , Esofagite Eosinofílica/diagnóstico , Humanos , Masculino
4.
Clin J Gastroenterol ; 13(2): 276-280, 2020 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-31317370

RESUMO

Trimethoprim/sulfamethoxazole is well known to cause intra-hepatic cholestasis which in rare instances can be prolonged and lead to vanishing bile duct syndrome. The risk regarding the potential for cross-reactivity between structurally related molecules such as dapsone and trimethoprim/sulfamethoxazole in causing hepatotoxicity is scarce. Herein, we report a case of vanishing bile duct syndrome following dapsone use in a patient with HIV infection and a recent history of trimethoprim/sulfamethoxazole-induced cholestasis. The patient had severe and protracted cholestasis during 2 years of follow-up and eventually died of liver failure.


Assuntos
Anti-Infecciosos/efeitos adversos , Colestase Intra-Hepática/induzido quimicamente , Dapsona/efeitos adversos , Infecções por HIV/tratamento farmacológico , Combinação Trimetoprima e Sulfametoxazol/efeitos adversos , Anti-Infecciosos/administração & dosagem , Anti-Infecciosos/farmacologia , Anti-Infecciosos/uso terapêutico , Dapsona/administração & dosagem , Dapsona/farmacologia , Dapsona/uso terapêutico , Interações Medicamentosas , Quimioterapia Combinada , Evolução Fatal , Humanos , Masculino , Pessoa de Meia-Idade , Síndrome , Combinação Trimetoprima e Sulfametoxazol/administração & dosagem , Combinação Trimetoprima e Sulfametoxazol/farmacologia , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
5.
ACG Case Rep J ; 6(6): e00094, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31616767

RESUMO

Transjugular intrahepatic portosystemic shunt (TIPS) is an important therapeutic tool available to decrease portal vein pressure in patients with cirrhosis and portal hypertension. TIPS is associated with various complications, and fistula formation is an important one to be noted. We present an unusual and interesting case of a patient who developed right-sided heart failure 5 months after TIPS placement. Diagnostic workup revealed an uncommon fistula between the celiac artery trunk and portal vein that was successfully treated with angiography-guided embolization, resulting in clinical improvement.

6.
Intractable Rare Dis Res ; 7(3): 196-199, 2018 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-30181941

RESUMO

Gastrointestinal (GI) arteriovenous malformations (AVMs) are a well-known source of bleeding with colon being the most common site, but they can also occur in rare locations like the esophagus which may present with life threatening bleeding. We report the case of a 51-year-old male with end stage renal disease (ESRD) presenting with hematemesis and acute on chronic anemia. Further investigation showed an esophageal AVM which is an unusual location and it was successfully treated with an endoscopic clip instead of argon plasma coagulation (APC) due to its challenging location and esophageal wall motion from breathing. The patient continued to be asymptomatic without any upper and lower GI bleeding during his 20 months follow up period after the endoscopic management. Review of literature showed only 10 cases of AVMs involving esophagus and the average age of presentation was 52 years with a male predominance. We also provide an overview of those cases in the discussion section below.

7.
J Clin Pharm Ther ; 43(6): 918-920, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-29969517

RESUMO

WHAT IS KNOWN AND STUDY OBJECTIVE: Carfilzomib is a newer drug approved for the treatment of relapsing and refractory multiple myeloma. It has been rarely associated with acute liver failure (ALF). CASE SUMMARY: We present a case of 58-year-old man presenting with abnormal liver function tests and subsequently diagnosed with ALF due to carfilzomib. Liver enzymes improved significantly after discontinuation of the drug. WHAT IS NEW AND CONCLUSION: Even though ALF due to carfilzomib has been documented rarely in clinical studies, no detailed case report has been published so far. Patients on carfilzomib should be monitored for ALF, and prompt discontinuation of drug is necessary in such cases.


Assuntos
Antineoplásicos/efeitos adversos , Falência Hepática Aguda/induzido quimicamente , Mieloma Múltiplo/tratamento farmacológico , Oligopeptídeos/efeitos adversos , Antineoplásicos/administração & dosagem , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Doença Hepática Induzida por Substâncias e Drogas/patologia , Humanos , Falência Hepática Aguda/patologia , Testes de Função Hepática , Masculino , Pessoa de Meia-Idade , Oligopeptídeos/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...